<DOC>
	<DOCNO>NCT00571662</DOCNO>
	<brief_summary>This continuation pilot study regard phase II trial plan enroll additional 40 patient ( 20 relate 20 unrelated donor transplant ) hematological malignancy assess safety efficacy minimally myelosuppressive regimen pentostatin low-dose total body irradiation ( TBI ) follow allogeneic peripheral blood stem cell transplantation ( alloPSCT ) .</brief_summary>
	<brief_title>Safety Efficacy Pentostatin Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>This pilot study begin plan enroll 50 patient ( 20 relate 30 unrelated donor transplant ) hematological malignancy assess safety efficacy minimally myelosuppressive regimen Pentostatin low-dose total body irradiation ( TBI ) follow allogeneic peripheral blood stem cell transplantation ( alloPSCT ) . Patients persistent progressive malignancy transplantation treat GM-CSF ( cytokine therapy ) ass toxicity potential therapeutic efficacy . Patients persistent progressive disease fail qualify cytokine therapy portion study become candidate donor leukocyte infusion . The purpose protocol remain pilot study regard phase II trial plan enroll 40 ADDITIONAL patient ( 20 relate 20 unrelated donor transplant ) hematological malignancy assess safety efficacy modify version original preparative regimen Pentostatin low-dose total body irradiation ( TBI ) follow allogeneic peripheral blood stem cell transplantation ( alloPSCT ) . Patients fail become candidate donor-leukocyte infusion ( DLI ) . Primary Objectives 1 . To determine safety treat hematological malignancy establish donor hematopoietic chimerism use pentostatin low-dose total body irradiation follow allogeneic peripheral blood stem cell transplantation . 2 . To determine immunomodulatory effect pentostatin part condition regimen allogeneic peripheral blood stem cell transplantation . Secondary Objectives 1 . To determine incidence infection use minimally myelosuppressive condition regimen . 2 . To determine kinetics hematological immunological reconstitution allotransplantation minimally myelosuppressive condition regimen . 3 . To determine incidence chronic GVHD use allogeneic peripheral blood stem cell transplantation minimally myelosuppressive preparative regimen . 4 . To evaluate role preparative regimen donor source ( related versus unrelated ) inflammatory cytokine profile . 5 . To evaluate blood possible , biopsy specimen recently identify nuclear protein ( molecular weight 44/46 ) mononuclear cell obtain study subject . Interventions , evaluation , follow include : Pentostatin 4 mg/m^2/d intravenously day x 3 day administer 1000 cc NS hydration pentostatin ten day prior stem cell infusion ( day -10 , -9 , -8 ) . Total-body irradiation ( TBI ) : TBI 2.0 Gy give day -1 . Antiemetics give need . Patients receive one liter normal saline 2 hour pre TBI . A bone marrow biopsy aspiration cytogenetics flow cytometry perform Day +28 , Day +70 6 , 12 , 18 24 month follow transplant monitor hematologic recovery . DNA fingerprinting also conduct time 3 , 4 , 5 , 6 , 12 , 18 , 24 month determine chimerism .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age 1975 year 1 . Patients relapse autologous stem cell transplantation . 2 . Patients candidate autologous conventional allogeneic stem cell transplantation disease standpoint qualify functionally ( point view organ function , performance status ) myeloablative protocol . 3 . Any patient , opinion primary treat oncologist , nonmyleoablative therapy would treatment option best patient interest provide patient fit eligibility criterion protocol . Identification match related unrelated stem cell donor Diseases : Acute myelogenous leukemia first complete remission highrisk cytogenetics &gt; second complete remission minimal residual disease ( &lt; 10 % blasts* ) . Acute lymphocytic leukemia first complete remission highrisk cytogenetics &gt; second complete remission minimal residual disease ( &lt; 10 % blasts* ) . Chronic myelogenous leukemia first chronic phase , accelerate phase ( &lt; 10 % blasts* ) blast phase minimal residual disease ( &lt; 10 % blasts* ) second chronic phase . Chronic lymphocytic leukemia recurrence front line regimen ( relate donor transplant ) , chemorefractory disease ( unrelated donor transplant ) , TCLL partial remission minimal residual disease . Myelodysplastic syndrome refractory anemia without ringed sideroblast , RAEB , RAEBT , CMML ( &lt; 10 % blasts* ) . *both peripheral blood bone marrow Multiple myeloma receive least one regimen prior chemotherapy NonHodgkin 's Lymphomas : Small Lympho ( plasma ) cytic Lymphoma ( BSLL , BLPL ) : recurrence front line regimen ( relate donor transplant ) , chemorefractory disease ( relate unrelated donor transplant ) . Follicular LowGrade Lymphoma , Marginal Zone Lymphomas ( splenic , nodal , extranodal/MALT type ) : chemorefractory disease &gt; 2 prior regimen . Mantle Cell Lymphoma : first complete partial remission , refractory disease , fail prior ASCT . Diffuse Large Bcell Lymphoma , Follicular Large cell Lymphoma , Peripheral Tcell Lymphoma , Anaplastic Large Cell Lymphoma : refractory disease , fail prior ASCT . Burkitt Acute Lymphoblastic Lymphomas : highrisk disease remission , chemosensitive persistent recurrent disease . Cutaneous Tcell Lymphomas : ( Mycosis Fungoides , Sezary Syndrome ) : chemorefractory disease &gt; 2 prior regimen Hodgkins Disease : refractory persistent disease candidate ASCT , fail prior ASCT . Peripheral Tcell Lymphoma Age &gt; 75 year &lt; 19 year progressive disease within 8 week prior therapy within 12 week prior autologous stem cell transplantation Active CNS malignancy ( patient know positive CSF cytology parenchymal lesion visible CT MRI ) Fertile men woman unwilling use appropriate contraceptive technique 12 month follow treatment Females pregnant Patients HIV seropositive Active uncontrolled infection immediate lifethreatening condition time enrollment Significant Organ dysfunction : 1 . Calculated Creatinine Clearance &lt; 55ml/min 2. cardiac ejection fraction &lt; 40 % , NYHA class II great cardiac disease . 3 . DLCO &lt; 40 % , FEV1/FVC ratio &lt; 50 % predict , receive supplementary continuous oxygen 4. total bilirubin &gt; 2x upper limit normal ( unless due Gilberts disease malignancy ) , ALT AST 4x upper limit normal Karnofsky score &lt; 60 % Patients uncontrolled medical illness ( e.g. , uncontrolled systemic hypertension , diabetes ) Donor HLA genotypically match relative sibling firstdegree relative match HLAA , B , DR locus ( 6 antigen match ) acceptable donor HLA match unrelated volunteer donor unrelated donor match HLAA , B , DR locus ( 6 antigen match ) acceptable donor One antigen mismatch relate unrelated donor also acceptable , molecular typing need use H LAA , B , DR loci case mismatch unrelated donor . Donor Identical twin Pregnancy HIV positive Serious Allergy GCSF Current serious systemic illness Failure meet UNMC NMDP criterion donor</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>